Akcea Supports Rare Disease Day 2020 and Global Efforts to “Reframe Rare”
February 28, 2020 07:00 ET
|
Akcea Therapeutics, Inc.
BOSTON, Feb. 28, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the company’s support for Rare Disease...
Akcea Therapeutics to Present at the Cowen 40th Annual Health Care Conference
February 26, 2020 07:00 ET
|
Akcea Therapeutics, Inc.
BOSTON, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat...
Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2019
February 25, 2020 16:05 ET
|
Akcea Therapeutics, Inc.
Reported Full Year 2019 Global Net Product Revenues of $42 Million and Fourth Quarter 2019 Global Net Product Revenues of $14 Million Achieved the 2-2-2 plan: launched two products, initiated two...
Akcea Therapeutics to Hold Fourth Quarter and Full Year 2019 Financial Results Webcast
February 18, 2020 07:00 ET
|
Akcea Therapeutics, Inc.
BOSTON, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on...
Akcea Expands Board of Directors with Appointment of Dr. Amber Salzman
February 13, 2020 07:00 ET
|
Akcea Therapeutics, Inc.
BOSTON, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the appointment of Amber Salzman, Ph.D.,...
Akcea and Ionis report positive topline phase 2 study results of AKCEA-ANGPTL3-LRx
January 28, 2020 16:05 ET
|
Akcea Therapeutics, Inc.
Favorable safety and tolerability were observed Primary and multiple secondary endpoints were met with significant reduction in triglyceride levels, additional lipid parameters and ANGPTL3 ...
Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy
January 10, 2020 07:00 ET
|
Akcea Therapeutics, Inc.
BOSTON and CARLSBAD, Calif., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
New England Journal of Medicine Publishes Results from Phase 2 Study of AKCEA-APO(a)-LRx in Patients with Lp(a)-driven Cardiovascular Disease
January 02, 2020 08:00 ET
|
Akcea Therapeutics, Inc.
Patients treated with AKCEA-APO(a)-LRx received pre-specified endpoints for Lp(a) levels with favorable safety and tolerability profile Global Lp(a)HORIZON Phase 3 cardiovascular outcomes study...
Akcea Retains Rights to AKCEA-APOCIII-LRx
December 18, 2019 22:03 ET
|
Akcea Therapeutics, Inc.
BOSTON and CARLSBAD, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc....
Akcea Therapeutics Announces New Appointments to its Board of Directors
December 16, 2019 07:00 ET
|
Akcea Therapeutics, Inc.
BOSTON, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced the appointments of Lynne Parshall,...